EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Progress and Challenges in the Treatment of Fabry Disease

Malte Lenders, Elise Raphaela Menke, Eva Brand

BioDrugs · 2025-07 · 39 (4) · 517-535

DOI: 10.1007/s40259-025-00723-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioDrugs, online erschienen am 01.05.2025. Verfasst von Malte Lenders und 2 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine D (Nephrology, Hypertension and Rheumatology), and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Albert-Schw…. Hauptthemen laut MEDLINE: Fabry Disease, alpha-Galactosidase, Enzyme Replacement Therapy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universitätsklinikum Münster.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fabry disease is a rare but life-threatening, X-linked, inherited lysosomal storage disorder in which globotriaosylceramide is insufficiently metabolized because of reduced α-galactosidase A activity. Cellular globotriaosylceramide accumulation causes a multisystemic disease, which, if left untreated, reduces life expectancy in female and male individuals by around 10 and 20 years, respectively, leading to progressive renal failure, hypertrophic cardiomyopathy, cardiac arrhythmia, and premature cerebral infarction. The method of choice for confirming the diagnosis is the determination of reduced α-galactosidase A activity in leukocytes in male individuals and the molecular genetic detection of a disease-causing mutation in female individuals. Current approved treatment includes enzyme replacement therapy (agalsidase alfa [0.2 mg/kg body weight], agalsidase beta or pegunigalsidase alfa [both 1.0 mg/kg body weight]) every other week intravenously or, if a responding ('amenable') α-galactosidase A mutation is present, oral pharmacological chaperone therapy (migalastat 123 mg, every other day). Future therapeutic options may include substrate reduction therapy, gene therapy, messenger RNA therapy, and/or vesicle-packaged enzyme replacement therapy. This review presents current and future treatment options with advantages and disadvantages of the different treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fabry Diseasealpha-GalactosidaseEnzyme Replacement TherapyHumansGenetic Therapy1-DeoxynojirimycinIsoenzymesMaleFemaleRecombinant ProteinsMutationTrihexosylceramides

Substanzen

alpha-Galactosidaseagalsidase alfa1-DeoxynojirimycinmigalastatIsoenzymesagalsidase betaRecombinant ProteinsTrihexosylceramides

Autor:innen und Institutionen

  • Internal Medicine D (Nephrology, Hypertension and Rheumatology), and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany.
  • Internal Medicine D (Nephrology, Hypertension and Rheumatology), and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany. Eva.Brand@ukmuenster.de.

Förderung

  • Universitätsklinikum Münster

Zitieren

APA

Lenders, M., Menke, E. R., & Brand, E. (2025). Progress and Challenges in the Treatment of Fabry Disease. BioDrugs, 39(4), 517-535. https://doi.org/10.1007/s40259-025-00723-3

Vancouver

Lenders M, Menke ER, Brand E. Progress and Challenges in the Treatment of Fabry Disease. BioDrugs. 2025;39(4):517-535. doi:10.1007/s40259-025-00723-3

BibTeX
@article{Lenders2025,
  author = {Lenders, Malte and Menke, Elise Raphaela and Brand, Eva},
  title = {Progress and Challenges in the Treatment of Fabry Disease},
  journal = {BioDrugs},
  year = {2025},
  volume = {39},
  number = {4},
  pages = {517--535},
  doi = {10.1007/s40259-025-00723-3}
}
Kostenlos starten →